Skip to content

NASDAQ · small · thesis board

VERV Verve Therapeutics

In vivo base editing (PCSK9 / ANGPTL3)

View race

Thesis

Editorial summary — not a primary filing

In vivo base editing for cardiovascular genetics; VERVE-102 path is central.

Next gate

2026-11-12Company-guidedPh2 readout

Dose / safety update

91 days · Company: Company guidance

Survive-to-Event

ok

Cash covers the next gate with ~12 months spare (curated estimate).

Unverified estimate — not from a live SEC parse

Cash runway (~456d)100%
Days to gate (91d)20%
Show math

$480M cash ÷ $32M/mo burn ≈ 456 days. Source: curated SEC quarter figures.

Cash $480M as of 2026-03-31 (SEC)

Pipeline spine

  1. Preclinical
  2. Ph1
  3. Ph2
  4. Ph3
  5. Filed
  6. Approved

Rivals in this race

Open race →
NTLAPh3okCRSPPh1okBEAMPh1ok

Risks

  • Safety holds history
  • Dose finding
  • Cardiovascular bar
  • Runway

Source trail

  1. SECCash from latest reported quarter (curated)as of 2026-03-31
  2. ClinicalTrials.govNCT06164730as of 2026-07-01
  3. CompanyIR / press disclosuresas of 2026-07-01